GW professor receives $747,000 grant to research causes of severe intellectual disability and autism

NewsGuard 100/100 Score

As part of a national focus to better understand child health and development, Chiara Manzini, Ph.D., assistant professor of pharmacology and physiology at the George Washington University School of Medicine and Health Sciences, was awarded a $747,000 grant to research the causes of severe intellectual disability and autism.

With the support of this grant, Manzini and her research team will develop a model of intellectual disability and autism, caused by loss of function of the CC2D1A gene.

"We are exploring the function of the gene and of the mutation that causes disease, both using cell-based systems, analysis of neurons generated from animal models, and studying the behavior in mouse models to better understand the pathogenesis of the disease," said Manzini. "This gene regulates multiple signaling mechanisms inside the cells and we are hoping to understand these mechanisms first, to then figure out ways to modulate them to have an impact on the disease."

The grant, which started as a career development grant during Manzini's post doctorate career, was given by the Eunice Kennedy Shriver National Institute of Child Health & Human Development for her project, titled "Intracellular signaling in the development of human cognitive function." This grant is meant to act as a stepping stone to further Manzini's research, which will lay the ground work to study the treatment of the disease.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients